GlassScriptPhysician profile
Samuel Dean Brewster
NPI 1962491274
$4,134.37
in general payments reported to CMS, 2019-2025
47 companies · $843 in 2025
The $843 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $269 · 2021: $815 · 2022: $507 · 2023: $660 · 2024: $671 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.77 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.11 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.48 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $295.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $245.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $242.41 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $172.49 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $154.81 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.74 | 2021-2025 | Xifaxan |
| Amgen INC. | $141.22 | 2020-2024 | Prolia, Evenity, Repatha |
| Biohaven Pharmaceuticals, INC. | $120.08 | 2020-2021 | |
| Glaxosmithkline, LLC. | $109.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $88.76 | 2022 | |
| Merck Sharp & Dohme LLC | $88.64 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.47 | 2024-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $73.80 | 2019-2024 | Qelbree |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Brewster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.